Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. EOS imaging
  6. News
  7. Summary
    EOSI   FR0011191766


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

EOS imaging : corporate presentation - April 2021

04/20/2021 | 01:22pm EDT

Investor Presentation

Mike Lobinsky, CEO

Valérie Worrall, CFO

FY20 & 1Q21


This document has been prepared by EOS imaging (the "Company") and is provided for information purposes only.

The information and opinions contained in this document speak only as of the date of this document and may be updated, supplemented, revised, verified or amended, and such information may be subject to significant changes. EOS imaging is not under any obligation to update the information contained herein and any opinion expressed in this document is subject to change without prior notice.

The information contained in this document has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiary, its advisors and representatives accept no responsibility for and shall not be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained herein.

This document contains information on the Company's markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company's own estimates. Investors should not base their investment decision on this information.

This document contains certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. EOS imaging draws your attention to the fact that as forward-looking statements cannot under any circumstance be construed as a guarantee of the Company's future performance and that the Company's actual financial position, results and cash flow, as well as the trends in the sector in which the Company operate may differ materially

from those proposed or reflected in the forward-looking statements contained in this document. Furthermore, even if EOS imaging' financial position, results, cashflows and

developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this presentation. A description of those events that may have a material adverse effect on the business, financial position or results of EOS imaging, or on its ability to meet its targets, appears in the "Risk Factors" section of EOS imaging Financial Annual Report available on the Company's website.

Certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in the tables are therefore not necessarily equal to the sum of the individually rounded figures, amounts or percentages.

This document does not constitute or form part of an offer to sell or to purchase securities or the solicitation of an offer to purchase securities in the United States of America or in

any other jurisdiction. The securities mentioned in this presentation have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or under any other legislation of any jurisdiction in the United States of America and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act.

April 2021 2

EOS imaging: a leader in orthopedic medical imaging and software solutions

Unique, innovative, low dose 2D/3D full body imaging and software solutions bridging the gap between

imaging and orthopedic surgery

EOSedge: a disruptive imaging system with regulatory approvals in the U.S., Europe, Canada and Australia

EOS system, the first-generation system recognized worldwide with clearance to market in 51 countries incl. U.S. (FDA), Japan, China, and the European Union (CE), with over 400 units installed worldwide

A product portfolio targeting a ~€2 billion per year addressable market

Strategic partnerships in selected countries and direct commercial presence with offices in France (HQ),

U.S., Canada, Germany, and Singapore

> 160 employees, including an R&D team of 45 engineers

April 2021 3

Experienced Complimentary Management Team

Combined 120+ Years Medical Technology Experience

Mike Lobinsky - Chief Executive Officer

Carl Denys - VP Global Marketing

  • Over 20 years experience in Medical Device
  • Held senior management positions at Smith and Nephew, Brainlab, Blue Belt Technologies, Stryker Corp
  • Joined the company in 2017
  • Appointed CEO Jan 2019

Eric Maulave - Chief Operating Officer

  • Over 25 years of experience and began his career as business engineer for the IT and Multimedia sectors within the Philips Group.
  • Held various international positions as Sales and Marketing Director within the Philips Group.
  • Joined EOS imaging in 2012

Valerie Worrall - Chief Financial Officer

  • Over 20 years' experience in Finance in the
    Healthcare industry
  • She had a long tenure with Novartis and GSK and was also CFO of Balt, a French Medical device company
  • Joined EOS imaging in November 2018
  • Over 25 years of global medical industry experience in upstream/downstream marketing, business development, and sales operations.
  • Held senior management positions at IMRIS, St. Jude Medical, and Boston Scientific
  • Joined EOS imaging in 2020

Pascal Désauté - Chief Technology Officer

  • Over 18 years of experience in R&D and engineering in the healthcare market
  • 5 years of experience in R&D in mutli-energyX-ray cargo imaging
  • Contributed to the development of the gaseous detector of EOS, and to the overall device EOS
  • Joined EOS imaging in 1997

April 2021 4

Differentiated orthopedic imaging platform

Addressing Weaknesses of Conventional Imaging

Current orthopedic imaging modalities

Bone Imaging

Soft tissue imaging








Low dose

3D imaging




(no stitching)




full-body imaging

stitched imaging

*Only available in non-functional positions

April 2021 5

Pour lire la suite de ce noodl, vous pouvez consulter la version originale ici.


EOS imaging SA published this content on 20 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 April 2021 17:21:04 UTC.

ę Publicnow 2021
All news about EOS IMAGING
06/14EOS IMAGING : Opening of a period of early redemption for the bondholders from June 14 to ..
06/07Alphatec Holdings, Inc. and Eos Imaging Sa to Improve the Predictability of the Patient..
05/18EOS imaging SA Announces Board Changes
05/13Alphatec Holdings, Inc. completed the acquisition of EOS imaging SA.
05/11EOS IMAGING SA(ENXTPA : EOSI) dropped from CAC Small Index
04/21GLOBAL MARKETS LIVE : Ericsson, Netflix, Roche...
04/20EOS IMAGING : corporate presentation - April 2021
04/20Eos Imaging Sa Reports Earnings Results for the Full Year Ended December 31, 2020
04/20EOS IMAGING : 1st quarter earnings
04/20EOS IMAGING : Annual results
More news
Sales 2020 26,0 M 30,5 M 30,5 M
Net income 2020 -11,2 M -13,1 M -13,1 M
Net Debt 2020 20,1 M 23,5 M 23,5 M
P/E ratio 2020 -5,52x
Yield 2020 -
Capitalization 65,2 M 78,8 M 76,3 M
EV / Sales 2019 3,66x
EV / Sales 2020 3,14x
Nbr of Employees 157
Free-Float 4,26%
Duration : Period :
EOS imaging Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Michael Charles Lobinsky Chief Executive Officer & Director
ValÚrie Worrall Chief Financial Officer
GÚrard HascoŰt Chairman
Elisabeth Soubelet Chief Medical Officer
Maurice Delplanque Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)